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The inflammatory bowel diseases, consisting of Crohn’s disease, ulcerative colitis and indeterminate colitis, are distinguished by 
idiopathic and chronic inflammation of the digestive tract. The distinction between inflammatory bowel diseases and functional 
bowel disorders, such as irritable bowel syndrome, can be complex because they often present with similar symptoms. Rapid and 
inexpensive noninvasive tests that are sensitive, specific and simple are needed to prevent patient discomfort, delay in diagnosis, and 
unnecessary costs. None of the current commercially available serological biomarker tests can be used as a stand-alone diagnostic 
in clinics. Instead, these are used as an adjunct to endoscopy in diagnosis and prognosis of the disease.Along these lines,, fecal 
lactoferrin and calprotectin tests seem to be one step further from other tests with larger number of studies, higher sensitivity and 
specificity and wider availability. 
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INTRODUCTION
The inflammatory bowel diseases (IBD), consistsCrohn’s 
disease (CD), ulcerative colitis (UC) and indeterminate 
colitis (IC) which are distinguished by idiopathic and 
chronic inflammation of the digestive tract. These diseases 
have been shown to result from an aberrant innate and 
acquired immune response to commensal microorganisms in 
genetically susceptible individuals.1 Currently, the incidence 
of IBD is increasing worldwide, especially in Northern 
Europe and North America. Ethnic origin, lifestyle, presence 
of susceptibility regions on at least 12 chromosomes and 
geographical factors play a central role in the epidemiology 
of these diseases.2,3 
The distinction between IBD and functional bowel 
disorders, such as irritable bowel syndrome (IBS), can be 
complex since they often present with similar symptoms, 
including abdominal distention, pain and diarrhea, and 
therefore, invasive and expensive tests may be necessary. 
The diagnoses of IBDs depend on the clinical findings after 
radiological, endoscopic and histological examinations. 
Although the division between UC and CD is generally 
clear, indeterminate colitis is present in 10-20% of patients 
with isolated colitis.4 Noninvasive tests for both the 
diagnosis and follow-up of IBD have gained increasing 
attention. Rapid and inexpensive noninvasive tests that 
are sensitive, specific and simple are necessary to prevent 
patient discomfort, delay in diagnosis and unnecessary 
costs. The biomarkers of IBD, including serological 
tests, fecal markers and genetically predisposed gene 
polymorphisms, are tools for disease diagnosis, estimation 
of activity, follow-up and disease prognosis.5-7 Moreover, in 
conjunction with the development of imaging techniques, 
such techniques as imaging biomarkers with ultrasound, 
magnetic resonance imaging (MRI), X-ray, computer 
tomograghy (CT), position emission tomography (PET) 222
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and single photon emission computed tomography 
(SPECT) are also defined.8 
Therefore, the purpose of the present study was to 
critically review the current literature on the diagnosis 
and follow-up of inflammatory bowel diseases. We 
systematically searched Medline and the Cochrane Database, 
with no language restrictions, for studies of humans on 
the topic of IBD diagnosis that were published between 
January 1960 and August 2009. The key words inflammatory 
bowel diseases, Ulcerative colitis, Crohn’s disease, fecal 
calprotectin, lactoferrin, serology and their equivalent 
Medical Subject Heading terms were used.
SEROLOGICAL MARKERS
Serological testing has been used for many years 
in the diagnosis of IBDs. Serological biomarkers are 
primarily produced upon intestinal exposure to normal 
commensal bacteria9,10 and might reflect a disregulated 
immune inflammatory response.11,12 Most of the major 
serological biomarkers utilized in IBD clinics are antibodies 
to microbial antigens, including yeast oligomanna (anti-
Saccharomyces  cerevisiae, ASCA),  bacterial  outer 
membrane porin C (OmpC), Pseudomonas fluorescens 
bacterial sequence I2 (anti-I2) and, most recently, bacterial 
flagellin (CBir 1).13 
All of these antibodies are predominantly found in CD 
but are not found in UC, except ASCA, which is identified in 
5% of UC patients. On the other hand, the human antibody, 
perinuclear antineutrophil cytoplasm antibody (pANCA) 
is considered to be an autoantibody, although the specific 
antigenic stimulation for its production remains imprecise. 
PANCA has currently been found in up to 70% of patients 
with UC and in up to 20% of patients with CD.14
Five new anti-glycan antibodies anti-chitobioside 
IgA (ACCA), anti-laminaribioside IgG (ALCA), anti-
manobioside  IgG  (AMCA)  and  antibodies  against 
chemically synthesized (Σ) two major oligomannose 
epitopes, Man α-1,3 Man α-1,2 Man (ΣMan3) and Man 
α-1,3 Man α-1,2 Man α-1,2 Man (ΣMan4) are recognized 
recently.13,15 Since these new biomarkers have been shown 
to be present only in IBD, they might signify an intestinal 
inflammation that is specific to UC or CD. Moreover, these 
antibodies have been primarily studied in CD and have a 
high specificity but poor sensitivity. 
Joossens et al. investigated 86 families from Belgium 
and Northern France to test whether a combination of CD-
associated genes and/or antibody responses to microbial 
antigens might be valuable in identifying healthy relatives 
at risk. Genetic (NOD2, NOD1, TLR4, CARD8) and 
new serologic markers (ASCA, ACMA, ALCA, ACCA, 
ASigmaMA, OmpC, CBir1, I2) were analyzed in all of 
the subjects. After a follow-up of 54 months, the authors 
found that there was an additive risk for CD in subjects 
from multi-case families per additional affected relative and 
per additional positive antibody, and this was independent 
of NOD2 genetic marker.16 These new antibodies might 
be important in complicated disease phenotype and might 
predict the need for surgery.
Recently, Mokrowiecka studied 125 IBD patients (71 
UC, 31CD and 23 IC) and 45 patients with functional 
intestinal disorders to determine the accuracy of pANCA 
and ASCA in patients with IBD subgroups. In UC patients, 
the prevalence of pANCA was 68%, which was significantly 
higher than in CD (29%). ASCA were found significantly 
more often in CD (80.6%) than in UC patients (26.8%). 
The sensitivity, specificity, positive predictive value (PPV) 
and negative predictive value (NPV) of pANCA for UC 
diagnosis were 68%, 84%, 75% and 78%, respectively, and 
of ASCA for CD diagnosis were 81%, 78%, 45.5% and 
95%, respectively. Moreover, the combined use of these 
two markers provided changes in diagnostic accuracy, such 
that for pANCA+/ASCA- in UC the sensitivity, specificity, 
PPV and NPV of results were 42%, 100%, 100% and 43%, 
respectively, and for pANCA-/ASCA+ in CD the results 
were 52%, 98.6% 94% and 82%, respectively. The authors 
concluded that the specificity of these combined serological 
markers tended to be higher than their sensitivity, and thus, 
these markers are more useful in the differentiation of IBD 
subtypes than in screening the population.17 
Anand et al. evaluated 98 adults with IBD and found 
that ASCA and pANCA had a 32% sensitivity and 100% 
specificity for Crohn’s disease, while there was a 50% 
sensitivity and 90% specificity for UC.18 
Interestingly, in another study, the presence of ASCA 
was found to be associated not only with the existence of 
Crohn’s disease but also with markers of disease severity 
and oral involvement.19
Two  novel  immunoglobulin  A  (IgA)  cell  wall 
polysaccharide antibodies, anti-laminarin (anti-L) and 
anti-chitin (anti-C), were analyzed during the diagnosis 
and phenotype differentiation of Crohn’s disease and 
UC. A cohort of 818 individuals with IBD (517 CD and 
301 UC) were analyzed for seven anti-glycan antibodies 
(gASCA (anti-Saccharomyces cerevisiae) IgG, gASCA IgA, 
anti-chitobioside (GlcNAc(beta1,4)GlcNAc(beta)), anti-
laminaribioside (Glc(beta1,3)Glb(beta)), anti-mannobioside 
(Man(alpha1,3)Man(alpha)), anti-L and anti-C) and for 
pANCA. 20 The authors found that all of the glycan markers 
were specific for and more prevalent in CD than in UC and, 
additionally, that gASCA IgG and IgA best differentiated CD 
from UC, followed by anti-L. The authors concluded that 223
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anti-L and anti-C improved the ability to differentiate between 
CD and UC and that these antibodies were independently 
associated with a more aggressive CD phenotype. Chen et 
al. described the use of a whole E. coli proteome microarray 
as a novel high-throughput approach to screen and identify 
new serological biomarkers for IBD. With the use of protein 
arrays containing 4,256 E. coli K12 proteins, Chen et al. 
have identified novel sets of serological biomarkers for the 
diagnosis of IBD that have a >80% overall accuracy and 
sensitivity in differentiating CD from UC.21 
It is important to keep in mind that the diagnostic 
value of serological biomarkers can show a discrepancy 
among different ethnic or geographic groups. For instance, 
both ASCA and pANCA were found to be less sensitive 
in Chinese and Japanese patients, while the positivity of 
pANCA was shown to be higher in Mexican-American UC 
patients.22,23
It is also essential to emphasize that none of the current 
commercially available serological biomarker tests can be 
used alone as a diagnostic in clinics. Instead, they are used 
in addition to endoscopy in diagnosis and prognosis of the 
disease. Whether or not serologic markers have a role in 
screening for IBD remains controversial. However, due to 
the generally low sensitivity and specificity of these markers 
for distinguishing IBD from non-IBD, they are generally not 
recommended for use as a screening test. As a consequence, 
specific and sensitive IBD serologic biomarkers are desired, 
as well as future studies to evaluate the efficacy of current 
and newly identified biomarkers. 
BLOOD INFLAMMATORY MARKERS
Erythrocyte sedimentation rate (ESR), white blood cell 
count (WBC) and C-reactive protein (CRP) are known 
to be good predictors of disease activity in IBD. CRP, 
with its short half-life, becomes rapidly elevated soon 
after the onset of the inflammatory process and decreases 
after its resolution. Moreover evaluating CRP is simple, 
easily available and inexpensive. ESR is also inexpensive 
and easily available, but since it has a longer half-life it 
differs from CRP and causes a prolonged latency period 
after changes in IBD activity. In clinical practice, because 
ESR, WBC and CRP are non-specific, they sometimes are 
not helpful for the differential diagnosis and follow-up of 
IBD.24,25 
In addition, ESR has been found to be more reliable to be 
correlated with the disease activity.26 The pro-inflammatory 
cytokines (TNF-alpha, IL-1beta IL-6, and IL-8) are also 
found to be elevated in IBD patients.27 However, these 
are not widely available and are not specific for intestinal 
inflammation. 
FECAL MARKERS
Fecal markers comprise a heterogeneous group of 
substances that either pour out from, or are generated by, the 
inflamed intestinal mucosa.28 The fecal excretion of Indium 
111-labeled leukocytes is considered to be the gold standard 
fecal marker of inflammation, with a sensitivity of 97% 
for the diagnosis of IBD.29 Even though the use of radio-
labeling techniques remains very important for research 
studies, they are not recommended for routine use due to 
high cost, exposure to radiation and the need for 4 days of 
fecal collection.
Fecal levels of Alpha1 α1-antitrypsin, which is a 
protease inhibitor produced by the liver, macrophages and 
intestinal epithelium, are a useful indicator of IBD. Random 
levels of fecal Alpha1-antitrypsin levels are revealed to 
be useful in measuring CD activity, while testing a 72-h 
fecal clearance of Alpha1-antitrypsin is a useful method 
for quantification of intestinal protein loss.30,31 Although 
fecal α1-antitrypsin has been generally accepted as a 
useful marker of IBD, it is not routinely available and cost-
effective. 
Fecal excretion of another serum anti-proteinase, alpha2-
macroglobulin, is also increased in IBD patients. The 
levels of alpha2-macroglobulin in the feces have a positive 
relationship with the activity index in CD but not in subjects 
with UC.32 
The  neutrophil-derived  proteins,  lysozyme, 
myeloperoxidase, calprotectin, lactoferrin, and PMN-
elastase, are generally elevated in the feces of IBD 
patients.33-39 However, fecal lactoferrin and calprotectin are 
more appropriate for the differentiation of chronic IBD from 
IBS, and their increased levels show a positive relationship 
with the severity of inflammation. Some recent studies 
that deal with the relationship of fecal markers in IBD are 
summarized in Table 1.48-52, 59, 66, 68-74 
Fecal Lactoferrin
Lactoferrin is an 80-kDa iron-binding glycoprotein 
and a major component of the secondary granules of 
polymorphonuclear neutrophils. In intestinal inflammation, 
leukocyte infiltration of the mucosa causes a rise in 
lactoferrin concentration in the feces. Lactoferrin has 
antibacterial activity and is resistant to proteolysis in 
the feces. Lactoferrin can be detected using simple and 
inexpensive techniques since it has an excellent stability in 
the feces for 4 days since a commercial ELISA has been 
developed and is now widely available. A negative fecal 
lactoferrin test simply means that there is an absence of 
significant neutrophilic intestinal inflammation.40, 41 224
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Table 1 - Some recent studies about the fecal markers in the evaluation of IBD
Study Aim Patient Result Conclusion
Erbayrak et al48 To investigate the role of FC 
in evaluating IBD activity 
65 IBD and 20 IBS 
patients
ESR, CRP, and FCP values were higher 
in the IBD patients than in the control 
group, while the hgb level was lower in 
the IBD group. No statistically significant 
differences in FCP levels were detected 
between UC and CD patients.
FC was found to be strongly 
associated with colorectal 
inflammation indicating 
organic disease.
Schoepfer et al49 To evaluate the correlation 
between endoscopic disease 
activity and FC, CAI, CRP, 
and blood leukocytes in UC
134 UC patients and 48 
controls
FC levels were significantly lower in 
UC patients with inactive disease. The 
overall accuracy for the detection of 
endoscopically active disease was 89% for 
FC, 73% for CAI, 62% for elevated CRP, 
and 60% for leukocytosis.
 FC was the only marker 
that reliably discriminated 
inactive from active disease, 
emphasizing its usefulness 
for activity monitoring.
Eder et al50 To evaluate the diagnostic 
utility of the assessment of 
FC concentration in patients 
with CD.
31 CD and 12 IBS 
patients
Mean FC concentration in CD group 
was statistically higher than among IBS 
patients. There was a positive correlation 
between FC concentration and CRP, and 
negative--with hemoglobin concentration.
The assessment of FC 
concentration may be useful 
in differential diagnoses of 
CD and monitoring patients 
with CD.
Gisbert et al51 To determine the role of FC 
and FL in the prediction of 
IBD relapses
89 CD, 74 UC patients Sensitivity and specificity to predict 
relapse of IBD for FC (>150 microg/g) 
and FL were 69% and 69%, and 62% and 
65%, respectively. 
FC and FL determination 
may be useful in predicting 
impending clinical relapse- 
-in both CD and UC patients.
D’Inca et al52 To assess the role of 
calprotectin tests in 
predicting clinical relapse in 
IBD patients.
97 UC and 65 CD A significant correlation emerged between 
a positive FC test and the probability of 
relapse in UC patients. In CD patients, 
only cases of colonic CD showed a 
significant correlation between a positive 
FC test and the probability of relapse.
Measuring calprotectin may 
help to identify UC and 
colonic CD patients at higher 
risk of clinical relapse.
Jeffrey et al59 To investigate fecal tumor 
M2-PK in the differentiation 
of functional from organic 
bowel disease.
94 controls and 105 
outpatients of whom 14 
were diagnosed with 
organic bowel disease 
later
Sensitivity and specificity, for diagnosis 
of organic bowel disease were 93%, 92% 
for FC and 67%, 88% for tumor M2-PK, 
respectively.
Tumor M2-PK is able to 
differentiate organic from 
functional bowel disease 
but has a lower sensitivity, 
specificity, and predictive 
value than FC.
Wagner et al66 To evaluate FC as a marker of 
treatment outcome of relapse 
of IBD and, to compare FC 
with fecal myeloperoxidase 
(MPO) and fecal eosinophil 
protein X (EPX)
27 UC and 11 CD 
patients
A normalised FC level at the end of the 
study predicted a complete response in 
100% patients, whereas elevated FC level 
predicted incomplete response in 30%. 
Normalised MPO or EPX levels predicted 
a complete response in 100% and 90% 
of the patients, respectively. However, 
elevated MPO or EPX levels predicted 
incomplete response in 23% and 22%, 
respectively.
A normalised FC level 
has the potential to be 
used as a surrogate marker 
for successful treatment 
outcome in IBD patients. FC 
and MPO provide superior 
discrimination than EPX in 
IBD treatment outcome.
Lamb et al68 To evaluate FC and FL in 
identifying CD recurrence in 
symptomatic patients after 
ileocaecal resection
117 CD patients In patients with mild to moderately 
clinically active disease, FC and FL 
identified individuals with and without 
recurrent IBD. Faecal markers were more 
accurate at predicting clinical disease 
activity than CRP, platelet count or 
endoscopic appearance.
FC and FL are non-invasive 
tests that can help to identify 
disease recurrence in 
symptomatic postoperative 
patients.
Ashorn et al69 To identify new noninvasive 
test combinations for 
characterization of IBD in 
children and adolescents 
by comparing serological 
responses to microbial 
antigens.
73 children who 
underwent endoscopies 
because of suspicion 
of IBD and IBD was 
diagnosed in 60 patients 
(18 CD, 36 UC, 6 IC).
FC levels were elevated more frequently 
in IBD patients (89% vs 9%). ASCA 
antibodies were detected in 67% of 
patients with CD, The combination of 
the measurements of FC and serological 
responses to microbial antigens (ASCA, 
I2, and OmpW) identified 100% of CD 
patients (specificity 36%) and 89% of UC 
patients (specificity 36%).
Increased levels of 
serological responses to 
microbial antigens (ASCA, 
I2, and OmpW) and FC are 
evident in both CD and UC 
patients. The combination 
of these markers provides 
valuable, noninvasive tools 
for the diagnosis of IBD.225
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Study Aim Patient Result Conclusion
Walkiewicz et 
al70
To compare FC levels in 
IBD and healthy controls, 
to correlate FC levels with 
clinical disease activity, 
32 IBD patients and 34 
healthy controls
The IBD group had higher FC levels 
compared with control. Among those 
with clinical relapse, 90% had FC levels 
more than 400 mug/g in CD. Eighty-nine 
percent of CD encounters with FC levels 
less than 400 mug/g remained in clinical 
remission.
Among children with CD 
and in remission, FC levels 
may be useful in predicting 
impending clinical relapse.
Xiang et al71 To investigate possibility and 
clinical application of FC in 
determining disease activity 
of UC
66 UC and 20 control 
patients
The FC concentration in the patients 
with active UC was significantly higher 
than inactive UC which was higher than 
the control group. There was a strong 
correlation between the FC concentration 
and the endoscopic gradings for UC .
FC can reflect the disease 
activity of UC and can be 
used as a rational marker for 
intestinal inflammation in 
clinical practice. 
Ho et al72 To investigate FC as a 
biomarker in predicting 
the clinical course of acute 
severe UC
90 patients with acute 
severe UC requiring 
intensive in-patient 
medical therapy
FC was significantly higher in patients 
requiring colectomy, with a trend 
toward significance when comparing 
corticosteroid nonresponders and 
responders, as well as between infliximab 
nonresponders and responders 
FC levels are dramatically 
elevated in severe UC. 
This biomarker can predict 
response to first or second-
line medical therapy in this 
setting.
Sipponen et al73 To study the correlation 
of FC and FL with simple 
endoscopic score for Crohn’s 
disease (SES-CD) and 
histology.
24 CD patients with 87 
ileocolonoscopies
In ileocolonic or colonic disease, both FC 
and FL correlated significantly with colon 
SES-CD and colon histology. In patients 
with normal FC or FL levels, endoscopic 
and histology scores were significantly 
lower than in those with elevated 
concentrations. 
In ileocolonic and colonic 
disease, endoscopic score 
SES-CD and histological 
findings correlated 
significantly with FC and 
FL. 
Langhorst et al74 To compare the 
performance of FL, FC, 
polymorphonuclear 
neutrophil elastase (PMN-e), 
and CRP in patients with 
IBD to address whether these 
markers can differentiate IBD 
patients with endoscopically 
assessed inflammation;and 
they correlate with 
endoscopic severity of 
inflammation 
54 IBS, 42 UC, 43 CD 
patients
 UC or CD patients with active 
inflammation demonstrated significantly 
higher levels of FL, FC, and PMN-e 
in feces as well as serum-CRP when 
compared to patients with inactive 
inflammation and patients with IBS. FC 
showed the highest diagnostic accuracy 
in CD (81.4%), whereas FL was superior 
to the other markers in UC (83.3%). The 
comprehensive activity index yielded a 
further improvement of sensitivity and 
specificity, with a diagnostic accuracy of 
95.3% for UC patients.
The fecal markers FL, FC, 
and PMN-e are able to 
differentiate active IBD from 
inactive IBD as well as from 
IBS. 
FC: Fecal calprotectin, IBD:Inflammatory bowel disease, IBS: Irritable bowel syndrome, ESR: Erythrocyte sedimentation rate, CRP: C-reactive pro-
tein, UC: Ulcerative colitis, CD: Crohn disease, CAI: Clinical activity index, FL: Fecal lactoferrin, IC: Indetermined colitis. 
Table 1 - Some recent studies about the fecal markers in the evaluation of IBD (cont.)
Dai et al. studied a total of 177 fresh stool samples 
collected from 42 active UC, 17 inactive UC, 13 active 
CD, 5 inactive CD, 41 infectious bowel diseases, 25 IBS 
and 34 healthy volunteers to evaluate the relationship 
between fecal lactoferrin and intestinal inflammation by 
quantitative analysis. Fecal lactoferrin was found to be 
significantly higher in active IBD than in inactive IBD, IBS 
and infectious bowel disease. The sensitivity and specificity 
of fecal lactoferrin for UC were 92% and 88%, respectively, 
and for CD were 92% and 80%, respectively. As a result of 
this study, fecal lactoferrin was found to be a sensitive and 
specific marker in measuring the activity of IBD and a valid 
method for discriminating between inflammatory and non-
inflammatory bowel diseases.42
Kane et al. compared 104 CD, 80 UC and 31 IBS 
patients with 56 healthy controls to determine the sensitivity 
and specificity of fecal lactoferrin concentrations for IBD or 
IBS. The study found that fecal lactoferrin was 90% specific 
for identifying inflammation in patients with active IBD, and 
elevated levels of lactoferrin were 100% specific in ruling 
out IBS.43
Schopper et al. studied 64 patients with IBD (36 CD, 
28 UC), 30 with IBS and 42 healthy controls to determine 
the accuracy of fecal markers, CRP, blood leukocytes 
and antibody panels for discriminating IBD from IBS. 
In addition to CRP and blood leukocytes, blinded fecal 
samples were measured for calprotectin (PhiCal Tesr, 
ELISA), lactoferrin (IBD-SCAN, ELISA), Hexagon-226
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OBTI (immunochromatographic test for detection of 
human hemoglobin), and LEUKO-TEST (lactoferrin 
latex-agglutination test). Also, the blinded serum samples 
were measured for the ASCA (ELISA) and pANCA 
(immunofluorescence) antibodies. The authors found 
that fecal calprotectin and lactoferrin could accurately 
discriminate between IBD and IBS. Moreover, there was 
only a marginal improvement in diagnostic accuracy when 
ASCA and pANCA were also involved.44 
Another study of 20 patients with IBS, 36 with IBD (24 
CD, 12 UC) and 18 with other forms of colitis (8 infectious 
colitis, 5 ischemic colitis, 5 medication-induced colitis) 
was conducted to evaluate the accuracy of four different 
fecal markers in discriminating between IBS, IBD and 
other forms of colitis. In this study, blinded fecal samples 
were measured for calprotectin ( with PhiCal-Test, ELISA), 
lactoferrin (with IBD-SCAN, ELISA), with Hexagon OBTI 
(immunochromatographic test for detection of human 
hemoglobin) and with LEUKO-TEST (lactoferrin latex-
agglutination test). The overall accuracies for discriminating 
IBS from IBD or other forms of colitis were as follows: 
IBD-SCAN, 91%; PhiCal-Test, 89 %; LEUKO-TEST, 92%; 
Hexagon OBTI, 91%; C-reactive protein, 89%; and blood 
leukocytes, 92%. The differentiation of IBD from other 
forms of colitis usingfecal markers had an overall accuracy 
ranging from 43 to 50%. The feasibility of fecal sampling 
in outpatients was high, with an acceptance rate of 95%. In 
conclusion, the IBD-SCAN and PhiCal-Test had the best 
overall accuracy for the detection of colitis, followed by 
the LEUKO-TEST, Hexagon OBTI, C-reactive protein and 
blood leukocytes.45
Fecal lactoferrin might be a helpful noninvasive 
diagnostic tool for the detection of colitis; however, since 
it is unspecific, its role in the diagnosis and monitoring of 
IBD is still questionable. Further studies are necessary to 
determine its exact place in routine clinical practice. 
Fecal Calprotectin
Calprotectin is a calcium-binding protein that inhibits 
metalloproteinases, hasantibacterial and antifungal activities 
and induces apoptosis in malignant and nonmalignant 
cell cultures.46 Calprotectin constitutes 60% of neutrophil 
cytosolic proteins and is an abundant protein found in all 
body fluids in proportion to the degree of inflammation. 
Calprotectin has many clinical advantages. It is resistant 
to bacterial degradation in the gut and is stable in stool 
for up to one week at room temperature, allowing delays 
in transporting the sample to the laboratory. Furthermore, 
calprotectin can be readily quantified using ELISA. 
Notably, random stool samples of <5 g show calprotectin 
concentrations equivalent to 24-hour homogenized 
specimens, demonstrating that calprotectin is uniformly 
scattered throughout the feces.47
Since calprotectin is primarily derived from neutrophils, 
its concentration is directly proportional with neutrophil 
migration toward the intestinal tract. Many studies have dealt 
with the role of calprotectin in IBD diagnosis and follow-up 
(Table 1). The leukocyte proteins calprotectin, lactoferrin, 
lysozyme, myeloperoxidase, and PMN-elastase were 
compared in fecal samples of three consecutive feces (e.g., 
three days) in 40 healthy persons, 39 patients with chronic 
IBD (21 with CD and 18 with UC) and 40 patients with IBS. 
From this comparison, levels of all of the fecal leukocyte 
markers in IBS were found to be in the range of healthy 
patients. Moreover, fecal PMN-elastase and calprotectin 
still differentiated between chronic IBD and IBS and still 
correlated with the severity of inflammation.34
In our study of 65 IBD patients (14 CD and 51 UC) 
and 20 outpatients diagnosed with IBS according to Roma 
II criteria, fecal calprotectin was found to be strongly 
associated with colorectal inflammation, indicating the 
presence of organic disease.48
Another study was conducted to evaluate the correlation 
between endoscopic disease activity and fecal calprotectin. 
The results of the Clinical Activity Index (CAI), CRP and 
blood leukocytes in 134 UC patients found that endoscopic 
disease activity correlated closest with the presence of 
calprotectin. The overall accuracy for the detection of 
endoscopically active diseases (score >/=4) was 89% for 
calprotectin, 73% for CAI, 62% for elevated CRP and 60% 
for leukocytosis. In conclusion, fecal calprotectin was the 
only marker that reliably discriminated an inactive disease 
from mild, moderate and highly active diseases, highlighting 
its usefulness for monitoring activity.49 
In a different study of 31 patients diagnosed with 
CD, the mean calprotectin concentration in the CD group 
was statistically higher than that of the IBS patients. 
A concentration of 16.01 mg/l calprotectin had 67.7% 
sensitivity and 66.7% specificity in distinguishing between 
CD and IBS. In this respect,the assessment of fecal 
calprotectin concentration might also be useful for 
differentiating CD from IBSCD and IBS.50
Gisbert et al. followed up 163 patients (89 CD, 74 
UC) for 12 months who had been in clinical remission for 
6 months to determine the role of fecal calprotectin and 
lactoferrin in the prediction of IBD relapse. The authors 
reported that 26 patients (16%) relapsed during follow-up. 
Calprotectin concentrations in patients who had suffered a 
relapse were found to be higher than in patients who had 
not (239 +/- 150 versus 136 +/- 158 µgg/g; P < 0.001). 
The relapse risk was higher in patients that had high (>150 227
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µg/g) calprotectin concentrations (30% versus 7.8%; P < 
0.001) or positive lactoferrin (25% versus 10%; P < 0.05). 
The sensitivity and specificity of fecal calprotectin (>150 
µg/g) to predict relapse were 69% and 69%, respectively. 
The corresponding values for lactoferrin were 62% and 
65%, respectively. As a result, it was concluded that the 
determination of fecal calprotectin and lactoferrin might be 
useful in predicting an impending clinical relapse, especially 
during the following 3 months of remission, in both CD and 
UC patients.51
Similarly, in another study with 97 UC and 65 CD 
patients in clinical remission, a significant correlation 
was found between a positive calprotectin test and 
the probability of relapse in UC patients (P= 0.000). 
However, in CD patients, only cases of colonic CD had a 
significant correlation between a positive calprotectin test 
and the probability of relapse (P= 0.02).52 Although fecal 
calprotectin levels are considered to change with age, 50 
µg/g of the suggested cut-off level is considered to be useful 
for all age groups over 4 years old.53
However, there are 4 main handicaps of fecal calprotectin 
to be kept in mind: 
·	 In some studies, low-dose aspirin treatment did not in-
crease fecal calprotectin levels, although the use of non-
steroidal anti-inflammatory drugs (NSAIDs) might cause 
an increase in calprotectin levels due to NSAID-induced 
enteropathy in patients without IBD.54,55 
·	 Any bleeding in the body over 100 ml, including men-
strual bleedings, might increase fecal calprotectin lev-
els.56
·	 Some authors suggest that, although fecal calprotectin 
is considered to be evenly distributed, factors other than 
disease might contribute to the significant intraindividual 
biological variations of it57.
·	 Since levels of fecal calprotectin increase in any 
condition that causes neutrophil migration to the 
gut, including neoplasms and infections, the sensi-
tivity of fecal calprotectin is not as high as desired.
Fecal calprotectin is an easy, inexpensive, sensitive and 
specific way to evaluate IBD. Despite the fact that levels 
of fecal calprotectin have an important role in diagnosis, 
follow-up, prediction of relapses and assessment of response 
to treatment, it still has some disadvantages and can only be 
used as a complementary test. 
Fecal Pyruvate Kinase 
The dimeric isoform of M2-pyruvate kinase (tumor M2-
PK), suggested to be a marker of colorectal cancer, has also 
recently been suggested to be a marker of gastrointestinal 
inflammation.58 
Jeffery et al. studied 105 gastroenterology outpatients 
with a possible diagnosis of organic bowel disease and 94 
controls to investigate the role of fecal tumor M2-PK in the 
differentiation of functional disease from organic bowel 
disease. The sensitivity, specificity and positive and negative 
likelihood ratios for diagnosis of organic bowel disease 
were found to be, respectively, 93%, 92%, 11.6 and 0.07 
for calprotectin, and, respectively, 67%, 88% 5.6 and 0.18 
for tumor M2-PK. Calprotectin, in combination with tumor 
M2-PK, had a sensitivity of 64%, a specificity of 98% and 
likelihood ratios of 32 and 0.03. Tumor M2-PK was useful 
for the differentiation of organic disease from functional 
bowel disease but had a lower sensitivity, specificity and 
predictive value than calprotectin.59 
The clinical value of fecal pyruvate kinase in IBD 
patients requires further study. 
Rectal Nitric Oxide
Nitric oxide (NO) is an endogenously produced gas 
with numerous physiological roles. In response to acute 
proinflammatory cytokines, leukocytes and epithelial cells 
express inducible nitric oxide synthase (NOS), which leads 
to the production and accumulation of significant quantities 
of NO.60
The level of rectal NO correlates with disease activity in 
IBD patients and it markedly decreases in response to anti-
inflammatory treatment. This minimally invasive and rapid 
test is shown to be useful for discriminating between active 
bowel inflammation and IBS.61 Reinders et al. also studied 
23 healthy volunteers and 32 patients with IBD to compare 
calprotectin and rectal NO levels. These authors found that 
patients with IBD had greatly increased NO and calprotectin 
levels compared to healthy volunteers (p <0.001). Moreover, 
there was a weak correlation between rectal NO levels, 
disease activity and the number of loose stools in IBD 
patients (Spearman’s rho 0.37 and 0.51, respectively; p 
<0.05); interestingly, there was no correlation between NO 
and calprotectin levels.62 
Ljung et al. studied 22 UC and 24 CD patients to explore 
rectal nitric oxide (NO) as a biomarker for the treatment 
response in IBD. Patients with active UC and CD displayed 
markedly increased rectal NO levels compared to the 
controls. Rectal NO correlated weakly with disease activity 
in both UC and CD. Interestingly, the patients’ refractory to 
steroid treatment only slightly increased NO levels compared 
to those with a therapeutic response. In this respect, the 
rectal NO level might be a useful biomarker for the treatment 
response in IBD, since low NO levels are predictive of a 
poor clinical response to steroid treatment.63
However, although rectal NO is a minimally invasive 228
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test and more expensive than many other fecal tests. More 
studies are necessary to reveal the exact role of rectal NO 
levels in IBD patients. 
Fecal Myeloperoxidase
Myeloperoxidase, an enzyme that functions in the 
oxygen-dependent killing of microorganisms, is released 
from the primary granules of neutrophils during acute 
inflammation. The concentration of myeloperoxidase is 
also proportional to the number of neutrophils within that 
region.64 
Silberer et al. compared five different leukocyte proteins, 
calprotectin, lactoferrin, lysozyme, myeloperoxidase and 
PMN-elastase and determined their levels by immunoassay 
in the feces of patients with IBD and IBS and of healthy 
persons. The areas under the ROC curves of PMN-elastase 
and calprotectin were not significantly different (p = 0.327), 
whereas PMN-elastase or calprotectin vs. the other proteins 
were significantly different (p < 0.001). The results suggest 
that fecal PMN-elastase and calprotectin are important for 
the differentiation of chronic IBD from IBS. The authors 
also found that PMN-elastase and calprotectin levels were 
correlated with the endoscopically classified severity of 
inflammation but not the myeloperoxidase.34 
However, Peterson et al. found a relationship between 
fecal myeloperoxidase levels and the histological indices of 
disease activity in UC.65 
Similarly, Wagner et al. showed that normalized MPO 
levels predicted a complete response to treatment to 
treatmentin 100% of the patients, as did normalized fecal 
calprotectin levels. However, elevated MPO levels predicted 
an incomplete response in 23% patients.66
In this respect, myeloperoxidase might potentially 
be used as a surrogate marker for a successful treatment 
outcome in IBD patients, similar to calprotectin. Further 
investigations are necessary to identify the clinical role of 
fecal myeloperoxidase in IBD.
Fecal Eosinophil Protein X
Eosinophil protein X (EPX) is released by activated 
eosinophil granulocytes, which are abundant in the mucosa 
in active IBD.67 Fecal EPX levels are mainly studied as 
an indicator of the treatment outcome in relapses of IBD. 
Wagner et al. showed that normalized EPX levels have 
predicted a complete response to treatment in 90%; however, 
an incomplete response was predicted in 22% of the patients. 
In this respect, FC and MPO provide superior discrimination 
compared to EPX in IBD treatment outcome.66 Moreover, 
fecal EPX levels are also beneficial complements to 
endoscopical and histopathological evaluations in the daily 
care of patients with UC.65 Still, more studies are necessary 
to reveal the clinical role of fecal EPX in IBD. 
CONCLUSION
Since inflammatory bowel diseases are chronic, fast, 
easily available and inexpensive noninvasive tests that are 
sensitive, specific and simple are necessary for diagnosis 
and follow-up. A differential diagnosis of organic and 
inorganic diseases is also important since they might have 
similar symptoms. Along these lines, fecal lactoferrin and 
calprotectin tests seem to be one step further from other 
tests with larger number of studies, higher sensitivity and 
specificity and wider availability. 
Take-home points:
Ø	 None of the current commercially available serological 
biomarker tests can be used by themselvesin clinics for 
diagnosis and follow up. Instead, the tests are used as an 
adjunct to endoscopy in diagnosis and prognosis of the 
disease.
Ø	 The erythrocyte sedimentation rate (ESR), white blood 
cell count and C-reactive protein (CRP) are good predic-
tors of disease activity in irritable bowel diseases (IBDs). 
However, since they are non-specific, they are sometimes 
not helpful for the differential diagnosis and follow-up of 
IBD.
Ø	 Indium 111-labeled leukocytes are considered to be the 
gold standard fecal marker of inflammation, with a 97% 
sensitivity for the diagnosis of IBD. However, due to 
their high cost, the exposure to radiation and the need 
for prolonged fecal collections of 4 days, they are not 
recommended for routine use. 
Ø	 Even though fecal α1-antitrypsin and alpha2-macroglob-
ulin are generally accepted as useful markers of IBD, 
they are not routinely available or cost-effective. 
Ø	 Fecal lactoferrin might be a helpful as a noninvasive di-
agnostic tool for the detection of colitis; however, since 
it is unspecific, its role in diagnosis and monitoring of 
IBD remains questionable. Fecal calprotectin is an easy, 
inexpensive, sensitive and specific method with which 
to evaluate IBD. Although levels of fecal calprotectin 
are important in all diagnoses, follow-ups, predictions 
of relapses and assessment of response to the treatment, 
it still can only be used as a complementary test. 
Ø	 Tumor M2-PK differentiates organic disease from func-
tional bowel disease but has a lower sensitivity, specific-
ity and predictive value than does fecal calprotectin.
Ø	 Rectal nitric oxide is a minimally invasive test and is 
more expensive than many other fecal tests. 229
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Ø	  Fecal myeloperoxidase and eosinophil protein X have 
potential as a surrogate marker for the determination of 
successful treatment outcomes in IBD patients, similar to 
calprotectin.
Ø	 Further studies are necessary to elucidate the exact role 
of fecal markers in IBD evaluation. 
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